Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, has granted equity inducement awards to two new non-executive employees on June 30, 2025. The awards include 240,000 stock options at an exercise price of $0.94 per share and 150,000 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting quarterly thereafter. The RSUs will vest in four equal annual installments. These awards were granted under the Company's 2021 Inducement Plan and approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Opus Genetics (Nasdaq: IRD), una societ脿 biofarmaceutica in fase clinica specializzata in terapie geniche per malattie ereditarie della retina, ha assegnato premi azionari di incentivo a due nuovi dipendenti non esecutivi il 30 giugno 2025. I premi comprendono 240.000 opzioni su azioni con un prezzo di esercizio di 0,94 $ per azione e 150.000 unit脿 azionarie vincolate (RSU).
Le opzioni azionarie matureranno in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura trimestralmente. Le RSU matureranno in quattro rate annuali uguali. Questi premi sono stati concessi nell'ambito del Piano di Incentivo 2021 della Societ脿 e approvati dal Comitato per la Retribuzione in conformit脿 con la Regola 5635(c)(4) del Nasdaq.
Opus Genetics (Nasdaq: IRD), una compa帽铆a biofarmac茅utica en etapa cl铆nica enfocada en terapias g茅nicas para enfermedades hereditarias de la retina, ha otorgado premios de incentivos accionarios a dos nuevos empleados no ejecutivos el 30 de junio de 2025. Los premios incluyen 240,000 opciones sobre acciones con un precio de ejercicio de $0.94 por acci贸n y 150,000 unidades restringidas de acciones (RSU).
Las opciones sobre acciones se consolidar谩n a lo largo de cuatro a帽os, con un 25% consolid谩ndose despu茅s de un a帽o y el 75% restante consolid谩ndose trimestralmente. Las RSU se consolidar谩n en cuatro cuotas anuales iguales. Estos premios fueron otorgados bajo el Plan de Incentivos 2021 de la Compa帽铆a y aprobados por el Comit茅 de Compensaci贸n en cumplimiento con la Regla 5635(c)(4) de Nasdaq.
Opus Genetics (雮橃姢雼�: IRD)電� 鞙犾爠靹� 毵濍 歆堩櫂鞚� 鞙勴暅 鞙犾爠鞛� 旃橂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 6鞗� 30鞚检棎 霊� 氇呾潣 靸堧鞖� 牍勳瀯鞗� 歆侅洂鞐愱矊 欤检嫕 鞚胳劶韹半笇毳� 攵�鞐枅鞀惦媹雼�. 鞚措矆 鞚胳劶韹半笇鞐愲姅 欤茧嫻 頄夓偓 臧�瓴╈澊 $0.94鞚� 240,000欤� 鞀ろ啞 鞓奠厴瓿� 150,000臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� 韽暔霅╇媹雼�.
鞀ろ啞 鞓奠厴鞚� 4雲勳棎 瓯胳硱 甓岆Μ臧� 攵�鞐悩氅�, 1雲� 頉� 25%臧� 攵�鞐悩瓿� 雮橂ǜ歆� 75%電� 攵勱赴氤勲 攵�鞐惄雼堧嫟. RSU電� 4雲勳棎 瓯胳硱 鞐瓣皠 霃欖澕頃� 4須� 攵勴暊搿� 攵�鞐惄雼堧嫟. 鞚� 鞚胳劶韹半笇電� 須岇偓鞚� 2021雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)毳� 欷�靾橅晿鞐� 氤挫儊 鞙勳洂須岇潣 鞀轨澑鞚� 氚涭晿鞀惦媹雼�.
Opus Genetics (Nasdaq : IRD), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les th茅rapies g茅niques pour les maladies h茅r茅ditaires de la r茅tine, a accord茅 des r茅compenses d'incitation en actions 脿 deux nouveaux employ茅s non ex茅cutifs le 30 juin 2025. Ces r茅compenses comprennent 240 000 options d'achat d'actions 脿 un prix d'exercice de 0,94 $ par action et 150 000 unit茅s d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises sur une p茅riode de quatre ans, avec 25 % acquis apr猫s un an et les 75 % restants acquis trimestriellement par la suite. Les RSU seront acquises en quatre versements annuels 茅gaux. Ces r茅compenses ont 茅t茅 accord茅es dans le cadre du Plan d'Incitation 2021 de la Soci茅t茅 et approuv茅es par le Comit茅 de R茅mun茅ration conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq.
Opus Genetics (Nasdaq: IRD), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gentherapien f眉r vererbte Netzhauterkrankungen spezialisiert hat, hat am 30. Juni 2025 zwei neuen nicht gesch盲ftsf眉hrenden Mitarbeitern Aktienanreize gew盲hrt. Die Auszeichnungen umfassen 240.000 Aktienoptionen zu einem Aus眉bungspreis von 0,94 $ pro Aktie sowie 150.000 Restricted Stock Units (RSUs).
Die Aktienoptionen werden 眉ber vier Jahre erworben, wobei 25 % nach einem Jahr und die restlichen 75 % anschlie脽end viertelj盲hrlich vesten. Die RSUs werden in vier gleichen j盲hrlichen Raten vesten. Diese Auszeichnungen wurden im Rahmen des Inducement Plans 2021 des Unternehmens gew盲hrt und vom Verg眉tungsausschuss gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the 鈥淐ompany鈥�), today announced that, on June 30, 2025, it granted equity awards to two new non-executive employees as a material inducement to employment. The equity awards were granted under the Company鈥檚 2021 Inducement Plan, as amended, and were approved by the Compensation Committee of the Company鈥檚 Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards consisted of stock options to purchase an aggregate of 240,000 shares of the Company鈥檚 common stock and 150,000 restricted stock units (鈥淩SUs鈥�). The stock options have an exercise price of
About Opus Genetics
The Company is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases. The Company鈥檚 pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown encouraging early results. Additional programs include OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA. The Company is also advancing Phentolamine Ophthalmic Solution
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
[email protected]
Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]
Source: Opus Genetics, Inc.
FAQ
What equity awards did Opus Genetics (IRD) grant to new employees in June 2025?
What is the vesting schedule for Opus Genetics (IRD) stock options granted in June 2025?
How do the RSUs vest in Opus Genetics' (IRD) June 2025 inducement grants?
What was the exercise price for Opus Genetics' (IRD) stock options granted on June 30, 2025?
